Sorry, you need to enable JavaScript to visit this website.

Upcoming Trials

Upcoming Clinical Trials

Study Identifier Study Name Disorders / CDG Type(s) Therapeutic approach Eligibility Study Type Industry / Institution(s) Region Location Contact Persons Direct Link
A Multicenter, Open-Label, Withdrawal and Treatment Trial Assessing the Efficacy, Safety, and Tolerability of 2 Doses of CERC-801 in Subjects with Phosphoglucomutase-1 Deficiency Related Congenital Disorders of Glycosylation (PGM1-CDG) PGM1-CDG Drug: CERC-801 D-galactose supplement; Administration: Oral Diagnosis of PGM1-CDG Interventional Phase 2 Mayo Clinic/CHOP

United States

Eva Morava-Kozicz, MD, PhD
Dr. Andrew Edmondson, MD, PhD

Page modified at Monday, April 19, 2021 - 21:37